155 related articles for article (PubMed ID: 25231897)
1. Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.
Myngheer N; Allegaert K; Hattersley A; McDonald T; Kramer H; Ashcroft FM; Verhaeghe J; Mathieu C; Casteels K
Diabetes Care; 2014 Dec; 37(12):3333-5. PubMed ID: 25231897
[TBL] [Abstract][Full Text] [Related]
2. Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Della Manna T; Battistim C; Radonsky V; Savoldelli RD; Damiani D; Kok F; Pearson ER; Ellard S; Hattersley AT; Reis AF
Arq Bras Endocrinol Metabol; 2008 Nov; 52(8):1350-5. PubMed ID: 19169493
[TBL] [Abstract][Full Text] [Related]
3. Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
Wambach JA; Marshall BA; Koster JC; White NH; Nichols CG
Pediatr Diabetes; 2010 Jun; 11(4):286-8. PubMed ID: 19656320
[TBL] [Abstract][Full Text] [Related]
4. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
[TBL] [Abstract][Full Text] [Related]
5. Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Dupont J; Pereira C; Medeira A; Duarte R; Ellard S; Sampaio L
J Pediatr Endocrinol Metab; 2012; 25(3-4):367-70. PubMed ID: 22768671
[TBL] [Abstract][Full Text] [Related]
6. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
[TBL] [Abstract][Full Text] [Related]
7. Molecular and clinical features of K
Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
[TBL] [Abstract][Full Text] [Related]
8. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Lau E; Correia C; Freitas P; Nogueira C; Costa M; Saavedra A; Costa C; Carvalho D; Fontoura M
Arch Endocrinol Metab; 2015 Dec; 59(6):559-61. PubMed ID: 26331221
[TBL] [Abstract][Full Text] [Related]
9. The first case report of sulfonylurea use in a woman with permanent neonatal diabetes mellitus due to KCNJ11 mutation during a high-risk pregnancy.
Klupa T; Kozek E; Nowak N; Cyganek K; Gach A; Milewicz T; Czajkowski K; Tolloczko J; Mlynarski W; Malecki MT
J Clin Endocrinol Metab; 2010 Aug; 95(8):3599-604. PubMed ID: 20466780
[TBL] [Abstract][Full Text] [Related]
10. Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation.
Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
Diabet Med; 2020 Nov; 37(11):1956-1958. PubMed ID: 32634858
[No Abstract] [Full Text] [Related]
11. Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
Siklar Z; Ellard S; Okulu E; Berberoğlu M; Young E; Savaş Erdeve S; Mungan IA; Hacihamdioğlu B; Erdeve O; Arsan S; Oçal G
J Pediatr Endocrinol Metab; 2011; 24(11-12):1077-80. PubMed ID: 22308870
[TBL] [Abstract][Full Text] [Related]
12. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
13. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
Zung A; Glaser B; Nimri R; Zadik Z
J Clin Endocrinol Metab; 2004 Nov; 89(11):5504-7. PubMed ID: 15531505
[TBL] [Abstract][Full Text] [Related]
14. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Pearson ER; Flechtner I; Njølstad PR; Malecki MT; Flanagan SE; Larkin B; Ashcroft FM; Klimes I; Codner E; Iotova V; Slingerland AS; Shield J; Robert JJ; Holst JJ; Clark PM; Ellard S; Søvik O; Polak M; Hattersley AT;
N Engl J Med; 2006 Aug; 355(5):467-77. PubMed ID: 16885550
[TBL] [Abstract][Full Text] [Related]
15. No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.
Iafusco D; Bizzarri C; Cadario F; Pesavento R; Tonini G; Tumini S; Cauvin V; Colombo C; Bonfanti R; Barbetti F
Diabetologia; 2011 Oct; 54(10):2736-8. PubMed ID: 21822789
[No Abstract] [Full Text] [Related]
16. Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.
Walton-Betancourth S; Ashford J; Beardsall K; Gooding N; Gurnell EM; Hendriks E; Hysted H; Lee J; Thankamony A; Tseretopoulou X; Win M; Williams RM
Horm Res Paediatr; 2022; 95(5):476-483. PubMed ID: 35817008
[TBL] [Abstract][Full Text] [Related]
17. Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same
Stanik J; Barak L; Dankovcikova A; Valkovicova T; Skopkova M; Gasperikova D
Endocr Regul; 2020 Nov; 54(4):260-265. PubMed ID: 33885251
[No Abstract] [Full Text] [Related]
18. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
Yang W; Wei H; Sang Y
J Pediatr Endocrinol Metab; 2013; 26(7-8):743-6. PubMed ID: 24266052
[TBL] [Abstract][Full Text] [Related]
19. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
20. Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.
Begum-Hasan J; Polychronakos C; Brill H
J Pediatr Endocrinol Metab; 2008 Sep; 21(9):895-903. PubMed ID: 18924582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
